secwatch.observer — SEC 8-K summary
======================================

Issuer:     MUSTANG BIO, INC. (MBIO)
CIK:        0001680048
Form:       8-K
Filed at:   2025-02-27T23:59:59+00:00
Accession:  0001104659-25-018299
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.50
Item codes: 2.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Mustang Bio sells fixed assets to AbbVie for $1M, exits Worcester facility
--------------------------------------------------------------------------

- Closed sale of furniture, fixtures, equipment to AbbVie for $1.0M; lease terminated.
- Exits manufacturing facility in Worcester, MA; corporate HQ moved to Waltham, MA.
- Expects ~$2.0M cash savings over 24 months from lease termination.
- Plans to rely on academic partners and contract manufacturers for clinical trials.
- Aims to initiate MB-109 (HSV-1 oncolytic virus + CAR-T) trial for GBM in H2 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1680048/000110465925018299/0001104659-25-018299-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1680048/000110465925018299/tm257773d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-018299

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer